Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 2(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06515418Phase 2Terminated

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Role: lead

NCT06141889Phase 1Completed

Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

Role: lead

NCT04705597Phase 2Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

Role: lead

NCT05152641Phase 2Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

Role: lead

NCT04815603Phase 2Withdrawn

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

Role: lead

All 5 trials loaded